Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival

Head & Neck ◽  
2016 ◽  
Vol 38 (S1) ◽  
pp. E2083-E2090 ◽  
Author(s):  
Scott M. Glaser ◽  
Steven F. Mandish ◽  
Beant S. Gill ◽  
Goundappa K. Balasubramani ◽  
David A. Clump ◽  
...  
Keyword(s):  
Overall Survival ◽  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Anaplastic Thyroid Cancer ◽  
Patterns Of Care

Anaplastic Thyroid Cancer (ATC): Prognostic Factors, Patterns of Care, and Overall Survival

2016 ◽  
Vol 94 (4) ◽  
pp. 950-951 ◽  
Author(s):  
S.M. Glaser ◽  
S.F. Mandish ◽  
B.S. Gill ◽  
G. Balasubramani ◽  
D.A. Clump ◽  
...  
Keyword(s):  
Overall Survival ◽  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Anaplastic Thyroid Cancer ◽  
Patterns Of Care

scholarly journals Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3200
Author(s):  
Alessandro Prete ◽  
Antonio Matrone ◽  
Carla Gambale ◽  
Liborio Torregrossa ◽  
Elisa Minaldi ◽  
...  
Keyword(s):  
Overall Survival ◽  
Thyroid Cancer ◽  
Median Overall Survival ◽  
Clinical Problem ◽  
Anaplastic Thyroid Cancer ◽  
New Drugs ◽  
Poor Survival ◽  
Tumor Microenvironments ◽  
Genetic Features ◽  
Poorly Differentiated

PDTC and ATC present median overall survival of 6 years and 6 months, respectively. In spite of their rarity, patients with PDTC and ATC represent a significant clinical problem, because of their poor survival and the substantial inefficacy of classical therapies. We reviewed the newest findings about genetic features of PDTC and ATC, from mutations occurring in DNA to alterations in RNA. Therefore, we describe their tumor microenvironments (both immune and not-immune) and the interactions between tumor and neighboring cells. Finally, we recapitulate how this upcoming evidence are changing the treatment of PDTC and ATC.

Extrapulmonary small cell carcinoma: Prognostic factors, patterns of care, and overall survival

2020 ◽  
Vol 46 (9) ◽  
pp. 1596-1604 ◽  
Author(s):  
Steven F. Mandish ◽  
Jeremy T. Gaskins ◽  
Mehran B. Yusuf ◽  
Brendan P. Little ◽  
Neal E. Dunlap
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Patterns Of Care ◽  
Extrapulmonary Small Cell Carcinoma

scholarly journals Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Maria Graziella Catalano ◽  
Mariateresa Pugliese ◽  
Marco Gallo ◽  
Enrico Brignardello ◽  
Paola Milla ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Overall Survival ◽  
Thyroid Cancer ◽  
Disease Progression ◽  
Histone Deacetylase ◽  
Median Survival ◽  
Histone Deacetylase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Randomized Controlled ◽  
Deacetylase Inhibitor

Anaplastic thyroid cancer (ATC) has a median survival less than 5 months and, to date, no effective therapy exists. Taxanes have recently been stated as the main drug treatment for ATC, and the histone deacetylase inhibitor valproic acid efficiently potentiates the effects of paclitaxelin vitro. Based on these data, this trial assessed the efficacy and safety of the combination of paclitaxel and valproic acid for the treatment of ATC. This was a randomized, controlled phase II/III trial, performed on 25 ATC patients across 5 centers in northwest Italy. The experimental arm received the combination of paclitaxel (80 mg/m2/weekly) and valproic acid (1,000 mg/day); the control arm received paclitaxel alone. Overall survival and disease progression, evaluated in terms of progression-free survival, were the primary outcomes. The secondary outcome was the pharmacokinetics of paclitaxel. The coadministration of valproic acid did not influence the pharmacokinetics of paclitaxel. Neither median survival nor median time to progression was statistically different in the two arms. Median survival of operated-on patients was significantly better than that of patients who were not operated on. The present trial demonstrates that the addition of valproic acid to paclitaxel has no effect on overall survival and disease progression of ATC patients. This trial is registered withEudraCT 2008-005221-11.

scholarly journals Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

2018 ◽  
Vol 36 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Vivek Subbiah ◽  
Robert J. Kreitman ◽  
Zev A. Wainberg ◽  
Jae Yong Cho ◽  
Jan H.M. Schellens ◽  
...  
Keyword(s):  
Overall Survival ◽  
Thyroid Cancer ◽  
Overall Response Rate ◽  
Response Rate ◽  
Progression Free Survival ◽  
Anaplastic Thyroid Cancer ◽  
Braf V600e ◽  
Free Survival ◽  
Overall Response ◽  
Duration Of Response

Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. Methods In this phase II, open-label trial, patients with predefined BRAF V600E–mutated malignancies received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death. The primary end point was investigator-assessed overall response rate. Secondary end points included duration of response, progression-free survival, overall survival, and safety. Results Sixteen patients with BRAF V600E–mutated anaplastic thyroid cancer were evaluable (median follow-up, 47 weeks; range, 4 to 120 weeks). All patients had received prior radiation treatment and/or surgery, and six had received prior systemic therapy. The confirmed overall response rate was 69% (11 of 16; 95% CI, 41% to 89%), with seven ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached as a result of a lack of events, with 12-month estimates of 90%, 79%, and 80%, respectively. The safety population was composed of 100 patients who were enrolled with seven rare tumor histologies. Common adverse events were fatigue (38%), pyrexia (37%), and nausea (35%). No new safety signals were detected. Conclusion Dabrafenib plus trametinib is the first regimen demonstrated to have robust clinical activity in BRAF V600E–mutated anaplastic thyroid cancer and was well tolerated. These findings represent a meaningful therapeutic advance for this orphan disease.

scholarly journals Classification, gradation, prognostic factors and risk factors for thyroid carcinoma

2003 ◽  
Vol 50 (3) ◽  
pp. 56-60
Author(s):  
Vladan Zivaljevic ◽  
Ivan Paunovic ◽  
Aleksandar Diklic ◽  
Ksenija Krgovic ◽  
Rastko Zivic ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Thyroid Carcinoma ◽  
Multiple Endocrine Neoplasia ◽  
Endemic Goiter ◽  
Anaplastic Thyroid Cancer ◽  
External Radiation ◽  
Follicular Cells ◽  
Follicular Thyroid Cancer ◽  
Area Increase

Thyroid carcinomas arise from follicular cells (papillary, follicular, Hurthle, anaplastic), parafollicular cells (medullary) and stroma (lymphoma, sarcoma?). Gradation and prognostic factors are different for every one of histological type. Most patients with papillary and follicular thyroid cancer have an excellent prognosis. At the other extreme is anaplastic thyroid cancer whose usual mean survival can be measured in months. Exposure to external radiation and living in endemic goiter area increase the frequency of thyroid cancer. Medullary thyroid carcinoma is often familial and may occur in associations with the multiple endocrine neoplasia syndromes.

Sign in / Sign up

Export Citation Format

Share Document